ED90 of Remimazolam Loading Dose for Sedation in Patients Under Monitored Anesthetic Care

Remimazolam Clinical Trial

Official title:

Determination of the Effective Dose 90 of Remimazolam Loading Dose for Adequate Sedation in Patients Undergoing Orthopaedic Surgery Under Monitored Anesthetic Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05340335
• Other study ID #: S2021-2407-0002
• Status: Completed
• Phase: Phase 4
• Start date: April 18, 2022
• Est. completion date: May 2, 2022

Study information

• Verified date: July 2022
• Source: Asan Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Currently used drugs for monitored general anesthesia include propofol, midazolam, and dexmedetomidine. Each drug has different advantages and disadvantages. Remimazolam causes a relatively small decrease in blood pressure, and it has no injection pain. In addition, remimazolam has a very short onset time, and even after the continuous infusion, the onset of remimazolam is fast, and even after continuous injection, the effect disappeared very quickly due to the short context-sensitive half time. nd through continuous infusion, the patient's depth of anesthesia can be maintained constant. In addition, the short duration of action and the ability to quickly reverse the effect of flumazenil suggest that remimazolam can be used effectively under general anesthesia as well as under general anesthesia. Remimazolam can be used as a continuous infusion for general anesthesia. However, it has also been reported to be used for sedation by continuous infusion or divided intravenous infusion. However, the effective infusion dose of remimazolam for supervised general anesthesia without mechanical ventilation has not been established.

In this study, the ED90 of the loading dose to induce loss of consciousness in patients when supervised general anesthesia is performed through continuous infusion of Remimazolam is to be obtained.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: May 2, 2022
• Est. primary completion date: May 2, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 80 Years

Eligibility

Inclusion Criteria:

• ASA PS 1-3

• Patients who are scheduled to undergo upper/lower limb surgery under the monitored anesthetic care with remimazolam

Exclusion Criteria:

• Patients who refuse to participate in this study

• Patients with hypersensitivity to benzodiazepine or flumazenil

• Patients with severe renal/hepatic disease

• Patients with drug/alcohol abuse

• Patients who take antidepressants, anticonvulsants, psychoactive drugs chronically

• Patients with difficulty in communication

• Patients with severe obstructive sleep apnea or other airway problems

• Patients contraindicated to regional anesthesia

• Patients judged to be inappropriate for this study

Related Conditions & MeSH terms

• Orthopedic Procedures
• Remimazolam
• Sedatives

Intervention

Drug:
• Remimazolam
A beginning dose of remimazolam is 1mg/kg/hr. When sedation is not achieved in 10 minutes, the dose will be increased by 0.1mg/kg/hr in the next patient. When sedation is successful, the same dose will be used with the probability of 0.89, or the dose will be decreased by 0.1mg/kg/hr with the probability of 0.11 in the next patient. (maximal dose: 2mg/kg/hr)

Locations

Country	Name	City	State
Korea, Republic of	Asan Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Asan Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Whether sedation was successful	MOAA/S score of 3 or less (MOAA/S: Modified Observer's Alertness/Sedation scale) Awake (5) - Unresponsive (0)	for 10 minutes from the initiation of the remimazolam administration
Secondary	Total amount of remimazolam for sedation	MOAA/S score of 3 or less	From the initiation of the remimazolam administration to the time when MOAA/S score of 3 or less, assessed up to 10 minutes
Secondary	Effect site concentration	Calculated by a computerized program(Asanpump)	From the initiation of the remimazolam administration to the time when MOAA/S score of 3 or less, assessed up to 10 minutes